title: Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine.
abstract: Atomoxetine has been shown to be safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD). The purpose of this post hoc analysis was to examine response trajectories of pediatric patients treated with atomoxetine. Data were pooled from 7 atomoxetine double-blind, placebo-controlled clinical trials conducted in pediatric patients between November 1998 and June 2004. Growth mixture modeling was applied to the investigator-rated ADHD rating scale (ADHDRS-Inv) and Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) scores in the randomized acute phase (6-9 weeks) to explore whether there were groups of patients who differed in their response to atomoxetine. Classification and regression tree analyses were performed to identify predictors that can help categorize subjects to different response profiles. Patients (N = 925) were mostly male (73%) and of the combined subtype (74%). Most patients had a response pattern characterized by gradual, modest improvement, while a smaller group experienced early, robust improvement.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA wietecha_linda_a@lilly.com.
authors.forename: Linda A
authors.initials: LA
authors.lastname: Wietecha
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Shufang
authors.initials: S
authors.lastname: Wang
authors.affiliation: NeuroScience, Inc, Herndon, VA, USA.
authors.forename: Keith E
authors.initials: KE
authors.lastname: Saylor
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Day
authors.affiliation: Eli Lilly Asia, Shanghai, People's Republic of China.
authors.forename: Sheng Hu
authors.initials: SH
authors.lastname: Wu
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: Doug
authors.initials: D
authors.lastname: Kelsey
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011437:Propylamines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D017678:Sex Distribution; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride
keywords: ADHD; atomoxetine; classification and regression tree (CART) analysis; growth mixture modeling (GMM) analysis